Inquis Medical’s AVENTUS Thrombectomy System Receives FDA 510(k) Clearance for Treatment of Pulmonary Embolism
June 16, 2025 09:30 ET – Pioneering device combines precision clot removal with autologous blood reinfusion to address unmet needs
News & articles
Trial Finds Inquis Medical’s AVENTUS Thrombectomy System Safe and Effective for Patients with Pulmonary Embolism
May 02, 2025 11:50 ET – Results of AVENTUS IDE Trial presented at SCAI Scientific Sessions Inquis Medical, a leading
Inquis Medical Completes Enrollment in U.S. Pivotal IDE Trial of the Aventus Thrombectomy System Designed to Treat Patients with Pulmonary Embolism
MENLO PARK, Calif. — January 13, 2025 – Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced
AVENTUS Thrombectomy System:Innovative Endovascular Solution for Pulmonary Embolism
November 26, 2024 – A case example highlights the function of the AVENTUS System for the removal of emboli and
Inquis Medical Announces $40 Million Series B Financing to Accelerate Advancement of Aventus Thrombectomy System Addressing Venus Thromboembolic Diseases
Nov 4, 2024 2:20 PM EST – MENLO PARK, Calif.–(BUSINESS WIRE)–Inquis Medical, a pioneering medical technology company specializing in advanced
Unmet Needs in the PE Thrombectomy Space
July 9, 2024 – With Steven Abramowitz, MD; Mehdi H. Shishehbor, DO, MPH, PhD; and Nora Tabori, MD What are